Friday, 14 Jun 2019

You are here

Methotrexate's Low Efficacy in Cutaneous Psoriasis

In a prospective, double-blind, randomized placebo-controlled study, Warren et al. studied the effect of an intensified methotrexate (MTX) in chronic plaque psoriasis and showed MTX to be effective and superior to placebo.  

A total of 120 patients who were MTX-naive adults with active plaque psoriasis patients were randomized to receive 16 weeks of subcutaneous injections of either methotrexate (17.5 mg/wk) or placebo. MTX doses could be escalated to 22.5 mg per week after 8 weeks if patients did not achieve ≥ PASI50% improvement. All patients received folic acid 5 mg per week. 

A PASI 75 response was achieved in 41% of MTX treated but only in 10% of placebo  treated patients (P = 0·0026) by week 16. Subcutaneous methotrexate was generally well tolerated, with no serious adverse events related to this treatment over the 52-week study.

Other analyses and skin biopsies at baseline and week 16 showed MTX clinical effect were mediated by decreases in CD3+ lymphocytes and T helper 17 cell-mediated cytokine transcription.

The authors note that these results are in line with other MTX trials in psoriasis, showing  PASI 75 responses of 36–42% i  3 previous studies using oral methotrexate. Nevertheless, these results are far less than that achieved using biologic therapies, especially the IL-17, IL-23 adn IL-12.23 inhibitors.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Recommendations for Exercise in Ankylosing Spondylitis

Australian researchers have assessed the problem of exercise in ankylosing spondylitis (AS). After posing 10 questions to 11 experts they have provided evidence and consensus-based ecommendations on exercise in AS.

Biologic Retention in Ankylosing Spondylitis Patients

A study of biologic-naïve patients with ankylosing spondylitis (AS) who started therapy with a tumour necrosis factor inhibitor (TNFi) shows that after 5 years only 46% are still on a TNFi and that some are able to lower the dose over time.

A nationwide Swedish Rheumatology register followed 2590 Bio-naïve AS who started a TNFi between 2006–2015.

Low Serious Infection Risk with Newer Agents in Psoriasis

JAMA Dermatology reports on a comparative cohort study of 107,707 psoriasis patients, finding a decreased risk of serious infections among users of apremilast, etanercept, and ustekinumab when compared with methotrexate.

Skyrizi (risankizumab) FDA Approved for Psoriasis

AbbVie has announced that the US FDA has granted the approval of Skyrizi (risankizumab-rzaa) for the treatment of moderate to severe plaque psoriasis. 

Skyrizi is an interleukin-23 (IL-23) inhibitor that was also recently approved in Canada and Japan. Skyrizi is the third IL-23 inhibitor (behind guselkumab [Tremfya] and tildrakizumab [Ilumya]) to be approved in the last year.

Higher Comorbidities in Hidradenitis Suppurativa

JAMA Dermatology reports that patients with hidradenitis suppurativa have significantly more comorbidities than do patients with psoriasis.

A cross-sectional study compared 5306 HS patients, 14 037 patients with psoriasis, and 1 733 810 controls from electronic health records between 2013 and 2018. Specifically they examined comorbidities using the Charlson Comorbidity Index (CCI) score.